Pharmacological inhibition of myostatin improves motor function in children with spinal muscular atrophy and is associated with an acceptable safety profile.

Source: Everyone is About to Become Lean and Muscly (new evidence)

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports

19score

Challenges

0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect

1 study reviewed

In plain English

Medications that block myostatin increase motor function in children with spinal muscular atrophy and do not cause unacceptable side effects.

See the scientific wording

Pharmacological inhibition of myostatin improves motor function in children with spinal muscular atrophy with an acceptable safety profile.

Why this might work

A drug blocks a protein that normally stops muscle growth, allowing muscle fibers to get bigger and stronger, which improves movement ability.

Verified mechanismbased on 1 study

1 study

Study: Evaluating the effects of mRK35 by targeting myostatin in the pressure-overloaded heart.
This study gave mice a drug that blocks myostatin, and their muscles got stronger and bigger—without serious side effects. That’s good evidence that the same kind of drug might help kids with spinal muscular atrophy move better.